Rheumatology:自身免疫性风湿病发病前不良妊娠结局的风险,一项系统综述

2022-08-09 紫菀款冬 MedSci原创

对诊断为风湿性疾病的患者中有关不良妊娠结局的现有证据进行了系统回顾,以确定是否存在临床前自身免疫性风湿病风险增加。

目的:与普通人群(GP)相比,自身免疫性风湿病(ARD)妇女发生不良孕期事件和胎儿妊娠并发症的风险增加,包括先兆子痫、宫内生长受限和小于胎龄。然而,目前还不明晰的是,在产后多年被诊断为ARD之前,患有“临床前ARD”(preARD)的妇女是否也存在这种不良妊娠结局(APO)风险。因此,该研究对诊断为风湿性疾病的患者中有关APO的现有证据进行了系统回顾,以确定是否存在preARD风险增加。

方法:该研究按照系统评价和荟萃分析首选报告项目指南(PRISMA)标准进行报告。使用在线PubMed数据库进行系统的文献综述。根据国际分类标准,PreSLE和preRA患者被定义为在随后几年中发生系统性红斑狼疮(SLE)或类风湿关节炎(RA)的患者

结果:共筛选了176篇文章,并选择了27篇原始文章进行最终分析PreRA是研究最多的一组,共进行了15项研究 (包含> 1600例妊娠案例),preSLE是研究第二多的preARD,共有14项研究 (包含> 1000例妊娠案例)。

该研究发现,与GP孕妇相比,随后发展为SLE的患者的APO负担增加;但与SLE妊娠相比,APO更少。相比之下,将preRA与GP妊娠进行比较时,发现APO的发生率相似

结论:该研究结果表明,preARD患者发生APO的风险增加,这突出了首次风湿病预约期间产科病史的相关性,以及预测APO的新筛查策略的必要性。需要进一步研究以阐明临床前和临床ARD中不良妊娠结局的免疫基础

文献来源:

Muñoz CM, Goulden B, Ahmed K, Alijotas-Reig J, Giles I. Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review [published online ahead of print, 2022 Aug 5]. Rheumatology (Oxford). 2022;keac417. doi:10.1093/rheumatology/keac417

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1971868, encodeId=52c019e186805, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Jul 22 23:52:54 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062600, encodeId=ac11206260007, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Sep 11 04:52:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392997, encodeId=f76b139299ea4, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469473, encodeId=182e14694e33b, content=<a href='/topic/show?id=850120501c5' target=_blank style='color:#2F92EE;'>#不良妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20501, encryptionId=850120501c5, topicName=不良妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa987034131, createdName=cmsvly, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1971868, encodeId=52c019e186805, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Jul 22 23:52:54 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062600, encodeId=ac11206260007, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Sep 11 04:52:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392997, encodeId=f76b139299ea4, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469473, encodeId=182e14694e33b, content=<a href='/topic/show?id=850120501c5' target=_blank style='color:#2F92EE;'>#不良妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20501, encryptionId=850120501c5, topicName=不良妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa987034131, createdName=cmsvly, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1971868, encodeId=52c019e186805, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Jul 22 23:52:54 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062600, encodeId=ac11206260007, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Sep 11 04:52:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392997, encodeId=f76b139299ea4, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469473, encodeId=182e14694e33b, content=<a href='/topic/show?id=850120501c5' target=_blank style='color:#2F92EE;'>#不良妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20501, encryptionId=850120501c5, topicName=不良妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa987034131, createdName=cmsvly, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1971868, encodeId=52c019e186805, content=<a href='/topic/show?id=8299e694421' target=_blank style='color:#2F92EE;'>#系统综述#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76944, encryptionId=8299e694421, topicName=系统综述)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8f4467, createdName=AspirantSuo, createdTime=Sat Jul 22 23:52:54 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062600, encodeId=ac11206260007, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun Sep 11 04:52:54 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392997, encodeId=f76b139299ea4, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469473, encodeId=182e14694e33b, content=<a href='/topic/show?id=850120501c5' target=_blank style='color:#2F92EE;'>#不良妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20501, encryptionId=850120501c5, topicName=不良妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa987034131, createdName=cmsvly, createdTime=Wed Aug 10 13:52:54 CST 2022, time=2022-08-10, status=1, ipAttribution=)]

相关资讯

ARD:上皮HIF2α表达诱导肠屏障功能障碍和关节炎恶化

HIF2α-密蛋白-15通路对于关节炎发作时肠道屏障功能的破坏至关重要,突出了肠道稳态与关节炎之间的功能联系。恢复或保护肠道屏障功能的干预措施,例如 HIF 阻断剂,可用于治疗性地抑制关节炎的发作。

饮食也能促进恢复?类风湿患者该这样吃

类风湿关节炎(RA)是一种病因尚未明了的慢性全身性炎症性疾病,已知的诱发因素包括遗传因素、环境因素等诸多其他因素。而环境因素是属对RA患病和病程影响可控可调节的重要外部因素,它包括有饮食、居住条件、工

A&R:滑膜炎症通路是抗TNF应答RA患者的特征

探究抗肿瘤坏死因子(TNF)治疗反应的机制基础,并确定滑膜中的转录组变化是否反映在外周蛋白标记物中。

ARD:类风湿性关节炎中对血清阳性亚群风险有大影响的序列变异多组学分析

指向JAK/STAT通路中因果基因的序列变异对血清阳性RA的影响最大,而与血清阴性RA的关联仍然很少。 

A&R:两种单克隆ACPA以PAD4依赖方式联合诱导小鼠腱鞘炎、疼痛和骨丢失

研究抗瓜氨酸蛋白抗体(ACPA)除了疼痛和骨丢失之外是否还能诱发腱鞘炎(RA的早期症状),以及这些症状是否依赖于肽基精氨酸脱氨酶(PAD4)。

A&R:类风湿关节炎患者暂时停用甲氨蝶呤1周与2周对季节性流感疫苗接种的影响

确定类风湿关节炎(RA)患者接种季节性流感疫苗后停用甲氨蝶呤(MTX)1周是否不劣于停用2周